We postulate that cancer cells have a selective advantage for FOXM1 and RHNO1 co-expression since FOXM1 drives RS and downstream oncogenic phenotypes such as genomic instability, while RHNO1 helps mitigate FOXM1-induced RS to a level more favorable to cancer cell survival. Here, RHNO1 is linked to cancer.